GeoWealth | $38,000,000 | (Aug 5, 2025)
Afaxys, Inc. | $8,000,000 | (Aug 5, 2025)
Comp AI | $2,600,000 | (Aug 5, 2025)
Certified by Founder
Lodge
Remedy Plan Therapeutics
start up
United States
- Gaithersburg, MD
- 14/05/2025
- Unknown
- $18,000,000
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedy’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. We are advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Remedy's lead asset is RPT1G. With a favorable efficacy and tolerability profile, RPT1G will be advancing to the clinic in 2024.
- Industry Biotechnology
- Website https://remedyplan.com/
- LinkedIn https://www.linkedin.com/company/remedy-plan/
Ceedar | $200,000 | (Aug 5, 2025)
Conversion | $28,000,000 | (Aug 5, 2025)
Approov Mobile Security | $6,641,429 | (Aug 5, 2025)
Q.ANT | $71,676,650 | (Aug 5, 2025)
BioConsortia, Inc. | $15,000,000 | (Aug 5, 2025)
Bidbus | $3,300,000 | (Aug 5, 2025)
Blue J | $122,000,000 | (Aug 5, 2025)
Deep Cogito | $13,000,000 | (Aug 5, 2025)
Streamline AI | $8,600,000 | (Aug 5, 2025)